非小細胞肺がん治療薬の世界市場2015-2019...市場調査レポートについてご紹介

【英文タイトル】Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Product profiles

PART 05: Introduction
Key market highlights

PART 06: Disease overview
Understanding the disease
Risk factors
Signs and symptoms
Diagnosis
Staging
Treatment
Epidemiology

PART 07: Pipeline portfolio
Information on pipeline candidates

PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 09: Market segmentation by molecule type
Biologics
Small molecules

PART 10: Market segmentation by route of administration
Oral
Parenteral

PART 11: Geographical segmentation

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape
Competitive scenario
Market analysis 2014
Other prominent vendors

PART 18: Key vendor analysis
AstraZeneca
Celgene
Eli Lilly
F. Hoffmann-La Roche
Pfizer

PART 19: Appendix
List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Types of non-small cell lung cancer
Exhibit 03: Gene mutations in non-small cell lung cancer
Exhibit 04: Risk factors for non-small cell lung cancer
Exhibit 05: Signs and symptoms of non-small cell lung cancer
Exhibit 06: Tests for diagnosis of non-small cell lung cancer
Exhibit 07: Staging of non-small cell lung cancer
Exhibit 08: Management of non-small cell lung cancer
Exhibit 09: Types of radiation therapy for non-small cell lung cancer
Exhibit 10: Photodynamic therapy uses light to actuate a drug in the body, which kills abnormal cells.Non-small cell lung cancer treatment algorithm
Exhibit 11: Phase III pipeline molecules for non-small cell lung cancer
Exhibit 12: Global non-small cell lung cancer therapeutics market 2014-2019 ($ billions)
Exhibit 13: Five forces analysis
Exhibit 14: Global non-small cell lung cancer therapeutics market segmentation by molecule type
Exhibit 15: Global non-small cell lung cancer therapeutics market segmentation by route of administration
Exhibit 16: Global non-small cell lung cancer market by geographical segmentation 2014
Exhibit 17: Impact of drivers
Exhibit 18: Impact of drivers and challenges
Exhibit 19: F. Hoffmann-La Roche: Global YoY growth and revenue of Avastin 2011-2014 ($ millions)
Exhibit 20: F. Hoffmann-La Roche: Key takeaways
Exhibit 21: Alimta: Global YoY growth and revenue 2011-2014 ($ millions)
Exhibit 22: Gemzar: Global YoY growth and revenue 2008-2011 ($ millions)
Exhibit 23: Eli Lilly: Key takeaways
Exhibit 24: Abraxane: Global YoY growth and revenue 2011-2014 ($ millions)
Exhibit 25: Celgene: Key takeaways
Exhibit 26: Iressa: Global YoY growth and revenue 2011-2014 ($ millions)
Exhibit 27: Iressa: YoY growth and revenue in Western Europe 2011-2014 ($ millions)
Exhibit 28: Iressa: YoY growth and revenue in established ROW 2011-2014 ($ millions)
Exhibit 29: Iressa: YoY growth and revenue in emerging markets 2011-2014 ($ millions)
Exhibit 30: AstraZeneca: Key takeaways
Exhibit 31: Xalkori: Global YoY growth and revenue 2012-2014 ($ millions)
Exhibit 32: Pfizer: Key takeaways
Exhibit 33: AstraZeneca: Business segmentation by revenue 2014
Exhibit 34: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 35: AstraZeneca: Geographical segmentation by revenue 2014
Exhibit 36: Celgene: Product segmentation by revenue 2014
Exhibit 37: Celgene: Product segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 38: Celgene: Geographical segmentation by revenue 2014
Exhibit 39: Eli Lilly: Business segmentation by revenue 2014
Exhibit 40: Eli Lilly: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 41: Eli Lilly: Geographical segmentation by revenue 2014
Exhibit 42: F. Hoffmann-La Roche: Business segmentation by revenue 2014
Exhibit 43: F. Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 44: F. Hoffmann-La Roche: Geographical segmentation by revenue 2014
Exhibit 45: Pfizer: Business segmentation by revenue 2014
Exhibit 46: Pfizer: Geographical segmentation by revenue 2014


【レポート販売概要】

■ タイトル:非小細胞肺がん治療薬の世界市場2015-2019
■ 英文:Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019
■ 発行日:2015年10月21日
■ 調査会社:Technavio
■ 商品コード:IRTNTR7475
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。